Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.6600
+0.05048.27%
Post-market: 0.66000.00000.00%19:13 EDT
Volume:306.50K
Turnover:191.12K
Market Cap:7.31M
PE:1.25
High:0.6700
Open:0.5913
Low:0.5900
Close:0.6096
Loading ...

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
09 Dec 2024

PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21

THOMSON REUTERS
·
09 Dec 2024

Lucid Diagnostics completes convertible debt refinancing

TIPRANKS
·
03 Dec 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

THOMSON REUTERS
·
03 Dec 2024

Press Release: Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Dow Jones
·
03 Dec 2024

Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test

TIPRANKS
·
20 Nov 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PR Newswire
·
20 Nov 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR Newswire
·
18 Nov 2024

PAVmed Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
17 Nov 2024

PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti

TIPRANKS
·
16 Nov 2024

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring

GuruFocus.com
·
15 Nov 2024

PAVmed Q3 2024 Adj. EPS $(0.54)

Benzinga
·
14 Nov 2024

PAVmed: Ongoing Initiatives Position PAVmed to Preserve Nasdaq Listing

THOMSON REUTERS
·
14 Nov 2024

PAVmed Inc: Qtrly Shr Loss $0.54

THOMSON REUTERS
·
14 Nov 2024

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire
·
14 Nov 2024

Lucid Diagnostics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024